CJC-1295 DAC vs Tesamorelin
A side-by-side research comparison of CJC-1295 DAC and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 DAC | Tesamorelin |
|---|---|---|
| Full name | CJC-1295 with Drug Affinity Complex | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | FDA Approved |
| Mechanism | The DAC moiety binds serum albumin creating a depot that slowly releases active CJC-1295 for continuous GHRH signaling. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 3,647 Da | 5,136 Da |
| Half-life | 8 days | 26-38 minutes |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 2 mg | 2 mg |
| Frequency | 1-2x per week | Once daily |
| Route | Subcutaneous | Subcutaneous injection |
CJC-1295 DAC reported benefits
- Once/twice weekly dosing
- Sustained IGF-1 elevation
- Convenient schedule
- Long-term body composition changes
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.